Laurus Labs (BOM:540222) Inventories, Finished Goods : ₹0 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs Inventories, Finished Goods?

Laurus Labs's annual finished goods increased from Mar. 2022 (₹4,819 Mil) to Mar. 2023 (₹4,998 Mil) but then declined from Mar. 2023 (₹4,998 Mil) to Mar. 2024 (₹0 Mil).

Laurus Labs Inventories, Finished Goods Historical Data

The historical data trend for Laurus Labs's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs Inventories, Finished Goods Chart

Laurus Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Inventories, Finished Goods

Get a 7-Day Free Trial

2,881.30

4,463.90

4,819.00

4,998.00

Laurus Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															4,998.00	-	-	-	-

Laurus Labs Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Laurus Labs (BOM:540222) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » Inventories, Finished Goods

Traded in Other Exchanges

LAURUSLABS:India

Address

Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.lauruslabs.com

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines